tldrdailynews.com logo

FDA Proposes Blocking Three GLP-1 Drugs From 503B Bulk List

1 min read
Source: fda.gov
FDA Proposes Blocking Three GLP-1 Drugs From 503B Bulk List
Photo: fda.gov
TL;DR Summary

The FDA proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, saying there is no clinical need for outsourcing facilities to compound these drugs from bulk substances. The agency invites comments by June 29, 2026, and will consider them before a final determination, citing patient safety and the integrity of the drug-approval process.

Topics:business#503b-bulks-list#drug-compounding#fda#glp-1-therapies#health#public-comment
Share this article
  1. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List  fda.gov
  2. FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies  CNBC
  3. FDA proposes curbs on mass copycats of Novo, Lilly's weight-loss drugs  USA Today
  4. Novo Nordisk stock rises on FDA compounding proposal  Investing.com
  5. Eli Lilly, Novo Nordisk Stocks Jump as FDA Moves Against Bulk Production of Obesity Drug Ingredients  TipRanks

Reading Insights

Total Reads

1

Unique Readers

4

Time Saved

2 min

vs 2 min read

Condensed

86%

384 → 55 words

Want the full story? Read the original article

Read on fda.gov